Kensey Nash Looks To Augment TriActiv Embolic Protection Offerings
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash is counting on the next-generation TriActiv Fx and TriActiv ProGuard embolic protection systems to substantially strengthen its endovascular business
You may also be interested in...
Kensey Nash’s Orthopedics Business Fortified By New Customers
Kensey Nash inked major supply agreements in the second quarter, expanding the firm's customer base and accelerating the rebound of its biomaterials business
Kensey Nash touts TriActiv FX results
The 3.2% major adverse cardiac event (MACE) rate seen in the firm's prospective ASPIRE registry "is the lowest recorded to date from a sizable multi-center study of the [saphenous vein graft] population, and is less than half of the next best data set widely quoted by the cardiology community," the company said March 7. The results also demonstrate a 2.2% incidence of heart attacks with the TriActiv FX embolic protection system. Kensey Nash will showcase the registry data at the American College of Cardiology meeting in Atlanta this week (1"The Gray Sheet" Feb. 6, 2006, p. 10)...
Kensey Nash touts TriActiv FX results
The 3.2% major adverse cardiac event (MACE) rate seen in the firm's prospective ASPIRE registry "is the lowest recorded to date from a sizable multi-center study of the [saphenous vein graft] population, and is less than half of the next best data set widely quoted by the cardiology community," the company said March 7. The results also demonstrate a 2.2% incidence of heart attacks with the TriActiv FX embolic protection system. Kensey Nash will showcase the registry data at the American College of Cardiology meeting in Atlanta this week (1"The Gray Sheet" Feb. 6, 2006, p. 10)...